Pfizer Makes Several Senior Executive Appointments - Quick Facts

(RTTNews) - Pfizer, Inc. (PFE) named Albert Bourla as group president of the vaccines, oncology and consumer healthcare business, and Susan Silbermann as president and general manager of global vaccines business, both effective January 1, 2014.

Silbermann has most recently led the vaccines portfolio within the Specialty Care business for the past year and a half.

Meanwhile, Amy Schulman steped down as general counsel and member of Pfizer's executive leadership team by mutual agreement. She will not assume role as head of vaccines, oncology and consumer healthcare business. She will only remain at the company for a transition period.

Doug Lankler will now assume the role of general counsel, and Rady Johnson will become chief compliance and risk officer, both effective immediately.

The company also noted that it will begin operating with three commercial businesses -- the Global Innovative Pharmaceutical business, led by Geno Germano; the Global Established Pharmaceutical business, led by John Young; and the Vaccines, Oncology and Consumer Healthcare business led by Albert Bourla, from January 1, 2014.

The company added that it remains on track to provide a 2014 baseline management view of profit and loss for each of these businesses, starting with the Q1 2014 quarterly results.